1 Title Page

2 Intraocular pressure, primary open-angle glaucoma and the risk of retinal vein occlusion:

- 3 a Mendelian randomization mediation analysis
- 4 **Authors:** Andreas Katsimpris¹, Sebastian-Edgar Baumeister², Nafsika Voulgari¹, Hansjörg
- 5 Baurecht ³, Stylianos Kandarakis ⁴, Michael Nolde ²
- 6
- 0
- 7
- 8

9 Affiliations

- 10 1. Princess Alexandra Eye Pavilion, University of Edinburgh, Edinburgh, UK
- 12 2. Institute of Health Services Research in Dentistry, University of Münster, Münster,
- 12 Germany
- 13 3. Department of Epidemiology and Preventive Medicine, University of Regensburg,
- 14 Regensburg, Germany
- 4. First Department of Ophthalmology, National and Kapodistrian University of Athens,
- 16 Athens, Greece

17 **Corresponding authors**

- 18 Andreas Katsimpris, Department of Ophthalmology, Princess Alexandra Eye Pavilion, University
- 19 of Edinburgh, Edinburgh, EH3 9HA, UK, email: a.katsimpris@gna-gennimatas.gr, telephone:
- 20 +447311299859, ORCID ID: <u>https://orcid.org/0000-0002-5805-105X</u>
- 21 Michael Nolde, Institute of Health Services Research in Dentistry, University of Münster,
- 22 Germany, email: nolde@uni-muenster.de, ORCID ID: https://orcid.org/0000-0001-6893-7367

Background: The etiological connection between intraocular pressure (IOP) and the risk of

23 Abstract

24

retinal vein occlusion (RVO) remains elusive, particularly regarding whether this risk emanates 25 from the direct influence of elevated intraocular pressure (IOP), irrespective of the presence of 26 27 primary open-angle glaucoma (POAG), or if it arises as a consequence of the sequelae of 28 POAG. Therefore, we conducted a Mendelian Randomization (MR) mediation analysis to elucidate the mediating role of POAG in the association between IOP and RVO. 29 Methods: We identified 47 single-nucleotide polymorphisms (SNPs) associated with IOP (P-30 value $< 5 \times 10^{-8}$) leveraging data from a genome-wide association study (GWAS) (N = 97,653) 31 32 obtained from the UK Biobank and 50 SNPs associated with POAG (P-value < 5x10⁻⁸) from a 33 GWAS meta-analysis (16,677 cases and 199,580 controls). We related these SNPs with RVO 34 using a GWAS of 775 RVO cases and 376,502 controls from FinnGen. By utilizing univariable and multivariable MR analyses we calculated the total effect of IOP on RVO and estimated the 35 36 degree to which POAG mediates this association.

Results: MR analyses showed that higher IOP is associated with higher RVO risk (odds ratio of
RVO per 1 mmHg increase in IOP: 1.53; 95% confidence interval: 1.04 to 2.26; p-value = 0.03).
Moreover, our MR mediation analysis suggested that 91.6% of the total effect of IOP on RVO
risk was mediated through POAG. The primary results were consistent with estimates of
pleiotropy-robust MR methods.

42 Conclusion: Our findings suggest that higher IOP increases the risk of RVO and that the
43 majority of this effect is mediated through POAG.

44

46 Introduction

47 Retinal vein occlusion (RVO) is the second most common retinal vascular disease following 48 diabetic retinopathy and an important cause of vision loss in individuals older than 80 years with 49 a prevalence of 4.6% [1]. Risk factors for RVO are mainly related to atherosclerosis, but also 50 conditions altering the rheologic properties in the retinal veins, such as hypercoagulability and 51 vasculitis [2].

52 Glaucoma, an ocular disorder characterized by optic nerve damage and visual field loss, has been implicated in the pathogenesis of RVO [3]. Specifically, the association between RVO and 53 primary open angle glaucoma (POAG) has been investigated in numerous studies, showing a 54 55 significantly higher prevalence of RVO in patients with POAG compared to the general population [3,4]. Different pathogenic mechanisms have been proposed, implicating intraocular 56 57 pressure which is a well-established and modifiable risk factor for glaucoma. On one hand, increased IOP has been hypothesized to collapse the retina vessel walls thus resulting in 58 59 occlusion [5,6]. On the other hand, structural changes of the vessels at the glaucomatous optic 60 discs might also make them more susceptible to thrombosis [7-10]. Whether RVO is caused by the effects of increased IOP independently from any glaucomatous optic disc abnormalities has 61 62 not been determined.

Mendelian randomization (MR) serves as a robust methodology utilizing genetic variants derived from genome-wide association studies (GWAS) as instrumental variables to elucidate the causal relationship between modifiable exposures and disease outcomes [11]. A recent MR study has identified a positive association between POAG and RVO [12]. However, it was not assessed whether this observed effect is intrinsic to POAG itself or if it is a consequence of the elevated intraocular pressure that is mediated through POAG. In addressing this gap, we conducted a MR mediation analysis to discern the mediating role of POAG in the relationship

- 70 between IOP and RVO and sought to enhance our understanding of the nuanced interplay
- 71 between these factors.

72

73 Materials and Methods

74 Study design

75 MR employs genetic variants as instrumental variables to investigate the impact of risk factors 76 on disease susceptibility [11]. This method mitigates susceptibility to confounding and reverse 77 causation, as these genetic variants are randomly assigned at conception, creating a guasi-78 randomized exposure allocation analogous to a randomized trial [11]. In our investigation, a two-79 sample MR was executed using summary statistics of single-nucleotide polymorphisms (SNPs) 80 obtained from GWAS focusing on IOP [13] and RVO [14]. The aim was to evaluate the influence of IOP on the risk of RVO. Moreover, we tried to assess the proportion of the effect of IOP on 81 RVO that is potentially mediated through POAG, by employing a two-step MR for mediation 82 analysis [15]. The study protocol was not pre-registered and our research adhered to the 83 84 STROBE-MR guidelines [16] and "Guidelines for performing Mendelian randomization 85 investigations" [17].

86 Data sources

87 Summary data for corneal-compensated IOP were obtained from the UK Biobank (UKBB)

cohort GWAS [13] (Supplementary Table 1). In particular, a subset comprising 97,653

individuals within the UKBB underwent ophthalmic evaluations, encompassing the quantification

90 of corneal-compensated IOP measured in millimeters of mercury (mmHg) through the

application of a non-contact tonometer. The preference for corneal-compensated IOP as the

- 92 selected exposure phenotype over regular IOP stems from its designed capability to
- 93 accommodate corneal biomechanical properties. Moreover, this metric has been previously

94 employed in GWAS for IOP [18]. Summary data for RVO were obtained from the FinnGen 95 consortium database's R9 release, involving a cohort of 775 documented RVO cases and 376,502 controls [14]. The FinnGen GWAS participants were of European origin, and the 96 identification of RVO cases adhered to diagnostic criteria established in either the International 97 98 Classification of Diseases, Ninth Revision (ICD-9) or International Statistical Classification of 99 Diseases, Tenth Revision (ICD-10) code. For the mediation MR analysis, GWAS summary statistics for POAG were also retrieved from a GWAS meta-analysis of 16,677 POAG cases and 100 101 199,580 controls of European ancestry [19] (Supplementary Table 1). POAG cases were 102 selected based on the ICD-9/ICD-10 criteria [19]. The genotyping, guality control, and imputation methods applied to the GWAS data used in our study have been detailed elsewhere 103 104 [14,19,20].

105 Selection of genetic variants as instrumental variables

We selected SNPs identified in the IOP GWAS that achieved genome-wide significance (P-106 value < $5^{10^{-8}}$, following clumping for linkage disequilibrium (LD) at r^2 < 0.001 over a 10mb 107 window [17]. The MR-Steiger directionality test was employed to discern the directions of the 108 causal relationship between IOP and RVO [21]. SNPs exhibiting a stronger correlation with the 109 110 outcome than the exposure were systematically excluded, as were those demonstrating notable influence in the funnel plots and scatter plots. Ultimately, we identified 47 SNPs associated with 111 112 IOP as instrumental variables. Furthermore, we quantified the proportion of variability in IOP that is explained by these 47 SNPs, through the summation of the coefficients of determination 113 (R^2) derived from the associations between the selected SNPs and IOP. Employing a similar 114 115 approach, we chose 50 SNPs from the GWAS on POAG for utilization in our MR mediation analysis. 116

118 Statistical analysis

After the process of data harmonization based on HapMap3 [22], the removal of strand-

ambiguous variants, and the alignment of association estimates, we proceeded to calculate

121 Wald ratios. We calculated these ratios by dividing the logarithm of odds ratio per allele for each

122 SNP identified in the GWAS for RVO by its respective estimate obtained from the IOP GWAS.

123 Subsequently, the total effect of IOP on RVO risk was assessed through a multiplicative random

124 effects inverse variance weighted (IVW) meta-analysis of the Wald ratios [23].

125 We implemented a univariable two-sample MR methodology, utilizing summary data extracted

126 from GWAS of IOP and RVO. Our two-sample MR analysis was based on three key

assumptions. Firstly, the imperative that the genetic variants selected should be associated with

the targeted risk factor, a principle known as the "relevance" assumption [24]. We adhered to

this assumption by choosing SNPs as instrumental variables that reached the threshold of

130 genome-wide significance (P-value $< 5^{*10^{-8}}$). Furthermore, we evaluated the strength of our

instrumental variables by assessing the F-statistic of the selected SNPs, concurrently examining

the proportion of variance in the exposure that they accounted for [25]. Secondly, the selected

133 genetic instruments should not be correlated with factors that could potentially confound the

relationship between the exposure and outcome, also known as the "exchangeability"

assumption [24]. Thirdly, the "exclusion restriction" assumption [24], where the genetic

instruments should not influence the outcome except through the risk factor of interest. While

the "exchangeability" and "exclusion restriction" assumptions are inherently unverifiable, we

138 executed sensitivity analyses to identify potential violations of these MR assumptions.

PhenoScanner [26] was employed to assess whether any of our selected genetic instruments were associated with phenotypes that could serve as potential confounders in our analysis. In instances where pleiotropic pathways were identified, we applied multivariable MR to adjust for these effects [27]. Moreover, we examined heterogeneity among our selected SNPs using the 143 Cochran Q heterogeneity test and I_{Gx}^2 [28] to detect pleiotropy, utilized several MR methods 144 proposed to enhance robustness in instances where genetic variants exhibit pleiotropy [29] (MR Egger regression, penalized weighted median, IVW radial regression, and MR-Pleiotropy 145 Residual Sum and Outlier (MR-PRESSO)) and performed a leave-one-out analysis to ascertain 146 147 if the IVW estimate was influenced by a singular SNP. 148 To further explore the mediating effect of IOP on RVO through POAG, we conducted a two-step MR for mediation analysis, as outlined in previous literature [15]. This process involves the 149 calculation of two distinct MR estimates: firstly, calculating the effect of IOP on POAG through a 150 151 univariable MR model, and secondly, assessing the effect of POAG on RVO using a multivariable MR model that includes an adjustment for IOP. The IOP estimate on POAG 152 multiplied with the adjusted POAG estimate on RVO provided the indirect effect of IOP on RVO, 153 154 mediated through POAG. We also quantified the proportion of the total effect of IOP on RVO 155 explained by the mediator (POAG) by dividing the calculated indirect effect of IOP on RVO by the total effect (adjusted direct and indirect effects of IOP on RVO). The delta method was 156 employed to derive 95% confidence intervals (95%CI) for the indirect effect [30]. Furthermore, 157 considering the inherent requirement for independence between the SNPs selected as 158 159 instruments for the exposure (IOP) and mediator (POAG) in MR mediation analysis, we ensured that the selected SNPs from the IOP and POAG GWAS datasets were non-overlapping [15]. 160 This precautionary step was essential to uphold the validity and integrity of the MR for mediation 161 162 analysis, preventing potential bias arising from SNP overlap. We conducted all analyses with R version 4.2.1 [31] using the MVMR (0.3), TwoSampleMR 163

164 (0.5.6), MendelianRandomization (0.5.1), MRPRESSO (1.0) and cause (1.2.0) packages.

165

167

168 Results

- 169 The 47 SNPs selected from the IOP GWAS (Supplementary Figure 1) accounted for 2.64% of
- the variability in IOP, with all SNPs displaying F-statistics of \geq 29.96 (Supplementary Table 2).
- 171 Employing the IVW method, genetically predicted IOP was positively associated with RVO risk
- 172 (OR = 1.53 per 1mmHg increase in IOP; 95%CI = 1.04 to 2.26; P-value = 0.03) (Figure 2 and
- 173 Supplementary Figure 2). Results from pleiotropy-robust MR methods aligned with the IVW
- analysis estimate (Figure 2). We found no associations of our selected SNPs with RVO risk
- 175 factors apart from POAG (Supplementary Table 3) and, thus, we refrained from conducting
- 176 multivariable MR to correct for potential correlated horizontal pleiotropy.
- 177 The Wald ratios for IOP with RVO did not exhibit heterogeneity (Supplementary Table 4) and
- the Cochran's Q heterogeneity test yielded a value of 37.89 (p-value = 0.797). Additionally, no
- 179 evidence for directional pleiotropy was found, since the intercepts from the MR-Egger analyses
- did not deviate from zero (Supplementary Table 4). The leave-one-SNP-out analysis did not
- identify any SNPs exerting significant influence on the IVW estimate for the association between
- 182 IOP and RVO risk (Supplementary Table 5).
- 183 An illustrative depiction of the MR mediation analysis can be seen in Figure 2. We found that
- 184 91.6% of the total effect of IOP on RVO was mediated through POAG (Supplementary Table 6).

185

186 Discussion

- 187 In this MR mediation analysis, we utilized genetic data to disentangle the causal pathway
- between IOP and RVO, and to also explore the mediating role of POAG in this relationship. Our
- results support a positive causal effect of IOP on RVO which is mostly mediated through POAG.

190 Many studies have examined the relationship between glaucoma, specifically POAG, and risk 191 for RVO [4]. Yin et al demonstrated in their meta-analysis that POAG is significantly associated with RVO risk (OR: 5.03; 95% CI: 3.97 to 6.37) [3]. Moreover, in their subgroup analysis, POAG 192 193 and chronic open angle-glaucoma were also correlated with central RVO (OR: 13.30; 95% CI: 194 3.34 to 53.20) and branch RVO (OR: 2.14; 95% CI: 1.09 to 4.20), but conclusions are guarded 195 due to the small number of studies included in the meta-analyses. Similarly, Na et al. 196 determined that the RVO incidence rate for the open-angle glaucoma patients was 528.95 per 197 100,000 person-years (95% CI: 515.46 to 542.79), 3.27 times higher than in the general 198 population [32]. Another Korean nationwide, population-based 11-year longitudinal study 199 showed that patients with POAG were under higher risk for developing RVO (HR: 3.27, 95% CI: 200 2.55-4.19) [33], while in the Beaver Dam Eye Study, no significant difference was found in the 201 age-adjusted 5-year incidence of RVO between participants with and without POAG [34]. 202 Different potential mechanisms have been proposed to interpret the association between POAG and RVO, and IOP has been shown to be a major contributing factor affecting retinal 203 hemodynamics. It has been suggested that increased IOP may compress blood vessels, 204 leading to proliferation of the vein intima and subsequently to the collapse of retinal vessel walls 205 206 [5]. The effects of this mechanical compression are more pronounced at the level of the lamina 207 cribrosa where the venous pressure is lowest. In older individuals with impaired retinal 208 circulation and compromised autoregulatory vascular mechanisms, even a slight increase in 209 IOP could be significant enough to decrease ocular blood flow, leading to venous slowing or 210 stasis [6]. Luntz et al. strongly support an etiological relationship between increased IOP and 211 central RVO having shown that the incidence of RVO in ocular hypertension is similar to that of POAG [35]. However, the Ocular Hypertension Treatment study, which included only 212 participants with ocular hypertension, did not find a significant difference in RVO incidence 213 214 between the observation and medication group [36].

215 The effect of IOP on retinal vessels might be further accentuated by anatomical characteristics 216 of the glaucomatous optic nerve head. The posterior bowing of the lamina cribrosa present in glaucomatous optic discs confers less glial support to the retinal vessels thus making them 217 more vulnerable to changes in IOP [8]. Also, higher cup-to-disc ratio has been correlated with 218 219 the development of RVO, postulating that optic disc cupping induces structural abnormalities to 220 the vessel at the disc, thus altogether making them susceptible to occlusion, venous stasis, and, consequently, to thrombosis, according to Virchow's triad [7,9,10]. On top of that, according to 221 222 the vascular theory of glaucoma pathogenesis, patients with POAG have narrower retinal 223 arteries and veins compared to normal individuals, predisposing them to greater vessel wall 224 compression following a rise in IOP [37]. Moreover, it has been hypothesized that RVO and 225 POAG could potentially arise from the same vascular abnormality given their shared vascular 226 risk factors. Optic disc hemorrhages frequently encountered in POAG and RVO indicate small 227 vein occlusions, raising the question of a common underlying pathway [38].

The key strength of this study is that it stands out as the first study to utilize the approach of MR 228 229 mediation analysis to disentangle the complex causal pathway between IOP, POAG and RVO. 230 Another strength of it lies in the consistency of association estimates obtained from pleiotropy-231 robust methods, aligning with the IVW estimate and indicating an absence of model violations. Nevertheless, certain limitations warrant consideration. Firstly, our investigation primarily 232 233 focused on delineating the mediating role of POAG in the association between IOP and RVO, 234 excluding exploration into other glaucoma subtypes such as primary angle-closure glaucoma. 235 Secondly, our MR models assumed a linear relationship between the identified risk factors and 236 the observed outcomes, whereas the true association among IOP, POAG, and RVO may manifest as non-linear. Thirdly, it is imperative to exercise caution when extrapolating the 237 genetic associations derived from European populations to other ethnic groups due to potential 238 239 population-specific variations. Fourthly, we did not assess the associations of IOP with the two

main subtypes of RVO, namely branch RVO and central RVO, since no GWAS datasets are

- 241 available for these phenotypes.
- In conclusion, our MR analyses infer an elevated risk of RVO associated with higher IOP. By
- 243 utilizing MR mediation analysis, our findings additionally suggest that the majority of the effect of
- 244 IOP on RVO risk is mediated through POAG. To advance our understanding of this intricate
- interplay, further investigations through population-based prospective studies, as well as
- experimental studies, are warranted to comprehensively explore the complex pathway involving
- IOP, POAG, and RVO.
- 248
- 249
- 250
- 251
- 252
- 253
- 254
- 255
- 256
- 257
- 258
- 259
- 255
- 260

261 Author contributions

- 262 KA, BSE and NM contributed to the study conception and design, drafted the manuscript and
- analyzed the data. All authors critically revised the manuscript for important intellectual content,
- 264 provided administrative, technical, or material support and approved the final version.

265 **Data availability**

- 266 The summary statistics for the intraocular for the UKBB GWAS are available at
- 267 https://pan.ukbb.broadinstitute.org (access date: 2023/10/12). The retinal vein occlusion
- summary statistics for the FinnGen GWAS are available at
- 269 https://www.finngen.fi/en/access_results (access date: 2023/10/12). The primary open-angle
- 270 glaucoma summary statistics are available at https://www.ebi.ac.uk/gwas/publications/33627673
- 271 (access date: 2023/10/12)
- 272 Additional information
- 273 Competing Interests: None declared
- Acknowledgments: We want to acknowledge the participants and investigators of the FinnGen
- and UK Biobank studies.
- 276

277

- 278
- 279
- 280

281

283 **References**

- 1 Mitchell, P., Smith, W. & Chang, A. Prevalence and Associations of Retinal Vein
- 285 Occlusion in Australia: The Blue Mountains Eye Study. Arch. Ophthalmol. 114, 1243-
- 286 1247, doi:10.1001/archopht.1996.01100140443012 (1996).
- 287 2 Kolar, P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of
- 288 published clinical data. *J Ophthalmol* **2014**, 724780, doi:10.1155/2014/724780 (2014).
- 289 3 Yin, X., Li, J., Zhang, B. & Lu, P. Association of glaucoma with risk of retinal vein
- 290 occlusion: A meta-analysis. Acta Ophthalmol. (Copenh.) 97, 652-659,
- doi:10.1111/aos.14141 (2019).
- Jabbehdari, S., Yazdanpanah, G., Cantor, L. B. & Hajrasouliha, A. R. A narrative review
- 293 on the association of high intraocular pressure and glaucoma in patients with retinal vein

294 occlusion. Ann Transl Med **10**, 1072, doi:10.21037/atm-22-2730 (2022).

- 295 5 Verhoeff FH. The effect of chronic glaucoma on the central retinal vessels. Arch
- 296 Ophthalmol. 1913;42:145–52.
- Frucht, J., Shapiro, A. & Merin, S. Intraocular pressure in retinal vein occlusion. *Br. J. Ophthalmol.* 68, 26-28, doi:10.1136/bjo.68.1.26 (1984).
- 299 7 Beaumont, P. E. & Kang, H. K. Cup-to-disc ratio, intraocular pressure, and primary
- 300 open-angle glaucoma in retinal venous occlusion¹. Ophthalmology 109,
- 301 282-286, doi:10.1016/S0161-6420(01)00922-8 (2002).
- Behrman, S. RETINAL VEIN OBSTRUCTION. Br. J. Ophthalmol. 46, 336-342,
- 303 doi:10.1136/bjo.46.6.336 (1962).
- 304 9 Dobree, J. H. Venous obstruction and neovascularization at the disc in chronic
- 305 glaucoma. *Trans. Ophthalmol. Soc. U. K.* **77**, 229-237; discussion 237-228 (1957).

Rubinstein, K. & Jones, E. B. Retinal vein occlusion: long-term prospects: 10 years'

306

10

follow-up of 143 patients. Br. J. Ophthalmol. 60, 148-150, doi:10.1136/bjo.60.2.148 307 308 (1976). 11 Sanderson, E. et al. Mendelian randomization. Nature Reviews Methods Primers 2, 6, 309 310 doi:10.1038/s43586-021-00092-5 (2022). 12 Zixun Wang, Zhiging Li. Causal Association between Glaucoma and Risk of Retinal 311 Vascular Occlusion: A Mendelian Randomization Study, 10 August 2023, PREPRINT 312 (Version 1) available at Research Square, doi:10.21203/rs.3.rs-3223120/v1. 313 314 13 Pan-UKB team. https://pan.ukbb.broadinstitute.org. 2020. Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated 315 14 population. Nature 613, 508-518, doi:10.1038/s41586-022-05473-8 (2023). 316 15 Carter, A. R. et al. Mendelian randomisation for mediation analysis: current methods and 317 challenges for implementation. Eur. J. Epidemiol. 36, 465-478, doi:10.1007/s10654-021-318 00757-1 (2021). 319 320 16 Skrivankova, V. W. et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and 321 322 elaboration. BMJ 375, n2233, doi:10.1136/bmj.n2233 (2021). 17 Burgess, S. et al. Guidelines for performing Mendelian randomization investigations: 323 update for summer 2023 [version 3; peer review: 2 approved]. Wellcome Open 324 325 Research 4, doi:10.12688/wellcomeopenres.15555.3 (2023). 326 18 Simcoe, M. J., Khawaja, A. P., Hysi, P. G. & Hammond, C. J. Genome-wide association 327 study of corneal biomechanical properties identifies over 200 loci providing insight into the genetic etiology of ocular diseases. Hum. Mol. Genet. 29, 3154-3164, 328 doi:10.1093/hmg/ddaa155 (2020). 329

- 330 19 Gharahkhani, P. et al. Genome-wide meta-analysis identifies 127 open-angle glaucoma
- 331 loci with consistent effect across ancestries. *Nature Communications* **12**, 1258,
- doi:10.1038/s41467-020-20851-4 (2021).
- Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
- 334 *Nature* **562**, 203-209, doi:10.1038/s41586-018-0579-z (2018).
- Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between
- imprecisely measured traits using GWAS summary data. *PLoS Genet.* **13**, e1007081,
- doi:10.1371/journal.pgen.1007081 (2017).
- Frazer, K. A. *et al.* A second generation human haplotype map of over 3.1 million SNPs. *Nature* 449, 851-861, doi:10.1038/nature06258 (2007).
- Burgess, S., Dudbridge, F. & Thompson, S. G. Combining information on multiple
- 341 instrumental variables in Mendelian randomization: comparison of allele score and
- 342 summarized data methods. *Stat. Med.* **35**, 1880 1906 (2015).
- 24 Labrecque, J. & Swanson, S. A. Understanding the Assumptions Underlying
- 344 Instrumental Variable Analyses: a Brief Review of Falsification Strategies and Related
- 345 Tools. *Curr Epidemiol Rep* **5**, 214-220, doi:10.1007/s40471-018-0152-1 (2018).
- Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey Smith, G. Mendelian
- 347 randomization: using genes as instruments for making causal inferences in
- epidemiology. *Stat. Med.* **27**, 1133-1163, doi:10.1002/sim.3034 (2008).
- 349 26 Kamat, M. A. et al. PhenoScanner V2: an expanded tool for searching human genotype-
- 350 phenotype associations. *Bioinformatics* **35**, 4851-4853,
- doi:10.1093/bioinformatics/btz469 (2019).
- 352 27 Sanderson, E. Multivariable Mendelian Randomization and Mediation. *Cold Spring Harb.*
- 353 *Perspect. Med.* **11**, doi:10.1101/cshperspect.a038984 (2021).

- Hemani, G., Bowden, J. & Davey Smith, G. Evaluating the potential role of pleiotropy in
- 355 Mendelian randomization studies. *Hum. Mol. Genet.* **27**, R195-R208,
- doi:10.1093/hmg/ddy163 (2018).
- 35729Slob, E. A. W. & Burgess, S. A comparison of robust Mendelian randomization methods
- using summary data. *Genet. Epidemiol.* **44**, 313-329, doi:10.1002/gepi.22295 (2020).
- 359 30 Ogasawara, H. Asymptotic standard errors of estimated standard errors in structural
- 360 equation modelling. Br. J. Math. Stat. Psychol. 55, 213-229,
- 361 doi:10.1348/000711002760554552 (2002).
- 362 31 R Core Team (2022). R: A language and environment for statistical computing. R
- 363 Foundation for Statistical Computing, Vienna, Austria. URL <u>https://www.R-project.org/</u>.
- 364 32 Na, K. I., Jeoung, J. W., Kim, Y. K., Lee, W. J. & Park, K. H. Incidence of retinal vein
- 365 occlusion in open-angle glaucoma: a nationwide, population-based study using the
- 366 Korean Health Insurance Review and Assessment Database. *Clin. Experiment.*

367 *Ophthalmol.* **46**, 637-644, doi:10.1111/ceo.13157 (2018).

- 368 33 Park, H. L., Jung, Y., Han, K., Lee, M. Y. & Park, C. K. Health care claims for primary
- 369 open-angle glaucoma and retinal vein occlusion from an 11-year nationwide dataset.
- 370 Sci. Rep. **7**, 8038, doi:10.1038/s41598-017-07890-6 (2017).
- 371 34 Klein, R., Klein, B. E., Moss, S. E. & Meuer, S. M. The epidemiology of retinal vein
 372 occlusion: the Beaver Dam Eye Study. *Trans. Am. Ophthalmol. Soc.* 98, 133-141;
 373 discussion 141-133 (2000).
- 374 35 Luntz, M. H. & Schenker, H. I. Retinal vascular accidents in glaucoma and ocular
 hypertension. *Surv. Ophthalmol.* 25, 163-167, doi:10.1016/0039-6257(80)90093-4
 376 (1980).
- 377 36 Barnett, E. M., Fantin, A., Wilson, B. S., Kass, M. A. & Gordon, M. O. The incidence of
- 378 retinal vein occlusion in the ocular hypertension treatment study. *Ophthalmology* **117**,
- 379 484-488, doi:10.1016/j.ophtha.2009.08.022 (2010).

380	37	Sonnsjö, B. & Krakau, C. E. Arguments for a vascular glaucoma etiology. Acta
381		<i>Ophthalmol. (Copenh.)</i> 71 , 433-444, doi:10.1111/j.1755-3768.1993.tb04615.x (1993).
382	38	Hayreh, S. S. Progress in the understanding of the vascular etiology of glaucoma. Curr.
383		Opin. Ophthalmol. 5 (1994).
384		
385		
386		
387		
388		
389		
390		
391		
392		
393		
394		
395		
396		
397		
398		
399		

400 Legends

- 401 **Figure 1.** Mendelian randomization estimates for the effect of intraocular pressure on retinal
- 402 vein occlusion. Estimates are reported as changes in odds of retinal vein occlusion per 1 mmHg
- 403 increase in intraocular pressure.

value
0.03
0.08
0.03
0.04
0

404

405 SNP, single nucleotide polymorphism; CI, confidence interval; MR-PRESSO, Mendelian

406 randomization pleiotropy residual sum and outlier.

407

408

409

410

411

412

414 **Figure 2.** Directed acyclic graphs of the mediation analysis with Mendelian randomization.



415

The indirect effect of intraocular pressure (IOP) on retinal vein occlusion (RVO) can be calculated by multiplying α times β , where α is the effect of IOP on primary open-anlge glaucoma (POAG), and β the effect of POAG on RVO. The proportion mediated can be estimated by dividing the indirect effect by the total effect of IOP on RVO. All estimates are shown as the difference in the logarithm of odds of the outcome, per 1 unit increase of the

- 421 exposure (continuous variables: IOP) or between the two exposure groups (binary variables:
- 422 POAG).